Literature DB >> 22099723

GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis.

Jian Rong Sheng1, Thiruppathi Muthusamy, Bellur S Prabhakar, Matthew N Meriggioli.   

Abstract

We and others have demonstrated the ability of granulocyte-macrophage colony-stimulating factor (GM-CSF) to suppress autoimmunity by increasing the number of CD4(+)CD25(+) regulatory T cells (Tregs). In the current study, we have explored the critical role of induced antigen specific Tregs in the therapeutic effects of GM-CSF in murine experimental autoimmune myasthenia gravis (EAMG). Specifically, we show that Tregs from GM-CSF treated EAMG mice (GM-CSF/AChR-induced-Tregs) adoptively transferred into animals with EAMG suppressed clinical disease more potently than equal numbers of Tregs from either GM-CSF untreated EAMG mice or healthy mice treated with GM-CSF. In addition, GM-CSF/AChR-induced-Tregs selectively suppressed antigen specific T cell proliferation induced by AChR relative to that induced by an irrelevant self antigen, (thyroglobulin) and failed to significantly alter T cell proliferation in response to an exogenous antigen (ovalbumin). These results are consistent with the hypothesized mechanism of action of GM-CSF involving the mobilization of tolerogenic dendritic cell precursors which, upon antigen (AChR) capture, suppress the anti-AChR immune response through the induction/expansion of AChR-specific Tregs.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22099723      PMCID: PMC3234297          DOI: 10.1016/j.jneuroim.2011.10.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  46 in total

1.  Regulatory T cells: the suppressor arm of the immune system.

Authors:  Sheila Langier; Kobe Sade; Shmuel Kivity
Journal:  Autoimmun Rev       Date:  2010-08-31       Impact factor: 9.754

Review 2.  Plasmacytoid dendritic cells and the regulation of immunoglobulin heavy chain class switching.

Authors:  Andrea Cerutti; Xugang Qiao; Bing He
Journal:  Immunol Cell Biol       Date:  2005-10       Impact factor: 5.126

Review 3.  Mechanisms of T regulatory cell function.

Authors:  Nadir Askenasy; Ayelet Kaminitz; Shai Yarkoni
Journal:  Autoimmun Rev       Date:  2008-03-24       Impact factor: 9.754

4.  Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis.

Authors:  Valeria Nessi; Sara Nava; Chiara Ruocco; Chiara Toscani; Renato Mantegazza; Carlo Antozzi; Fulvio Baggi
Journal:  J Immunol       Date:  2010-09-29       Impact factor: 5.422

5.  Antigen-independent development of Foxp3+ regulatory T cells suppressing autoantibody production in experimental pemphigus vulgaris.

Authors:  Tomoaki Yokoyama; Satoshi Matsuda; Yujiro Takae; Naoko Wada; Takeji Nishikawa; Masayuki Amagai; Shigeo Koyasu
Journal:  Int Immunol       Date:  2011-04-27       Impact factor: 4.823

6.  Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis.

Authors:  Matthew N Meriggioli; Jian Rong Sheng; Liangcheng Li; Bellur S Prabhakar
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

Review 7.  GM-CSF in inflammation and autoimmunity.

Authors:  John A Hamilton
Journal:  Trends Immunol       Date:  2002-08       Impact factor: 16.687

Review 8.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

9.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.

Authors:  M Cella; D Scheidegger; K Palmer-Lehmann; P Lane; A Lanzavecchia; G Alber
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

10.  Clinical uses of GM-CSF, a critical appraisal and update.

Authors:  Martha Arellano; Sagar Lonial
Journal:  Biologics       Date:  2008-03
View more
  25 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 2.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

Review 3.  Bridge between neuroimmunity and traumatic brain injury.

Authors:  Matthew L Kelso; Howard E Gendelman
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 4.  Microglial phenotypes in Parkinson's disease and animal models of the disease.

Authors:  Valerie Joers; Malú G Tansey; Giovanna Mulas; Anna R Carta
Journal:  Prog Neurobiol       Date:  2016-04-20       Impact factor: 11.685

5.  Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer's disease mice.

Authors:  Tomomi Kiyota; Jatin Machhi; Yaman Lu; Bhagyalaxmi Dyavarshetty; Maryam Nemati; Izumi Yokoyama; R L Mosley; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2018-03-17       Impact factor: 3.478

6.  GM-CSF-neuroantigen fusion proteins reverse experimental autoimmune encephalomyelitis and mediate tolerogenic activity in adjuvant-primed environments: association with inflammation-dependent, inhibitory antigen presentation.

Authors:  S M Touhidul Islam; Alan D Curtis; Najla Taslim; Daniel S Wilkinson; Mark D Mannie
Journal:  J Immunol       Date:  2014-07-21       Impact factor: 5.422

7.  CD1d(hi)CD5+ B cells expanded by GM-CSF in vivo suppress experimental autoimmune myasthenia gravis.

Authors:  Jian Rong Sheng; Songhua Quan; Betty Soliven
Journal:  J Immunol       Date:  2014-08-18       Impact factor: 5.422

8.  GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice.

Authors:  Lisa M Kosloski; Elizabeth A Kosmacek; Katherine E Olson; R Lee Mosley; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2013-10-29       Impact factor: 3.478

Review 9.  Functional defect in regulatory T cells in myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Qin Li Jiang; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

10.  Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis.

Authors:  Yan Li; Zhidan Tu; Shiguang Qian; John J Fung; Sanford D Markowitz; Linda L Kusner; Henry J Kaminski; Lina Lu; Feng Lin
Journal:  J Immunol       Date:  2014-07-23       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.